University of California San Diego-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of California San Diego - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013568
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of California San Diego (UCSD), a subsidiary of University of California, is a public research university that offers education and research with a portfolio of undergraduate, graduate, postdoctoral and professional schools. It offers courses in various fields including arts and humanities, biological sciences, physical sciences, engineering, management, international relations and pacific studies, medicine, oceanography, pharmacy and pharmaceutical sciences, and social sciences. It offers more than 100 undergraduate majors in six disciplinary areas; social sciences, engineering, biology, science/math, arts, humanities and special/undeclared. The university provides various courses through six undergraduate colleges, five academic divisions and five graduate and professional schools. It also offers research in the areas of neuroscience, nanoscience and climate science, and provides research funding opportunities. UCSD is headquartered in La Jolla, California, the US.

University of California San Diego – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California San Diego, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of California San Diego, Medical Devices Deals, 2011 to YTD 2017 11
University of California San Diego, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
University of California San Diego, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
UC San Diego Health Acquires San Diego Cancer Center 15
Partnerships 16
Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 16
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 17
Biomed Realty Trust Enters into Agreement with University of California San Diego 18
Galmed Pharma Enters into Agreement with University of California 19
Janssen Pharma Enters into Agreement with University of California, San Diego 20
AccentCare Forms Joint Venture With UC San Diego Health System 21
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 22
University of California and San Diego School of Medicine Partners with UC San Diego Moores Cancer Center 23
Pfizer Announces Co-Development Agreement With University Of California, San Diego 24
Regulus Therapeutics Enters Into Collaboration With University of California 26
Licensing Agreements 27
Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 27
Oncternal Therapeutics Enters into Licensing Agreement with University of California 28
Curtana Pharma Enters into Licensing Agreement with University of California San Diego 29
Abreos Biosciences Enter into License Agreement with University of California San 30
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 31
DesignMedix Enters into Licensing Agreement with University of California, San Diego 32
PsychoGenics Enters into Licensing Agreement with University of California, San Diego 33
Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 34
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 35
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 36
Batu Biologics Enters into Licensing Agreement with University of California, San Diego 37
PaxVax Enters into Licensing Agreement with University Of California, San Diego 38
SomPharma Enters into Licensing Agreement with University of California, San Diego 39
Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 40
Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 41
DevaCell Enters into Licensing Agreement with University of California, San Diego 42
Sanofi Pasteur Enters Into Licensing Agreement With University of California, San Diego 43
University of California San Diego – Key Competitors 44
University of California San Diego – Key Employees 45
University of California San Diego – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Strategy And Business Planning 48
Feb 08, 2016: UC San Diego Launches New Nonalcoholic Fatty Liver Disease Research Center 48
Government and Public Interest 50
Oct 23, 2017: Penn Radiology Researcher Awarded $3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 50
Oct 17, 2017: Pair of Discoveries Illuminate New Paths to Flu and Anthrax Treatments 51
Sep 27, 2017: Camino Pharma Co-founder Receives $10.8 Million Grant for Development of Potential Drug for Cocaine and Nicotine Addiction 53
Sep 13, 2017: Researchers develop new strategy to target KRAS mutant cancer 54
Jul 31, 2017: Organovo and UC San Diego Receive $1.7 Million Grant From National Institutes of Health to Study Liver Disease 55
Apr 21, 2017: Using CRISPR to Reverse Retinitis Pigmentosa and Restore Visual Function 56
Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 57
Dec 12, 2016: 3D Chemokine Receptor Study Opens Door to Finding New Anti-Inflammatory Drugs 59
Nov 18, 2016: New method helps identify antibiotics in mass spectrometry datasets 60
Nov 01, 2016: Researchers identify new drug target for gastrointestinal stromal tumors 62
Oct 17, 2016: FDA awards 21 grants to stimulate product development for rare diseases 63
Oct 04, 2016: Revolutionary Clinical Trial Initiative Focuses on Precision Medicine, Collaboration and Data Sharing to Transform Outcomes for All Pancreatic Cancer Patients 65
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 67
Sep 09, 2016: Six-day Clinical Trial Finds Integrative Medicine Program Alters Blood Serum 69
Sep 05, 2016: Promising drug leads identified to combat heart disease 70
Jul 21, 2016: Researchers ID cancer gene-drug combinations ripe for precision medicine 72
Jun 23, 2016: TSRI Scientists Reveal Single-Neuron Gene Landscape of the Human Brain 73
Jun 06, 2016: Novel imaging model helps reveal new therapeutic target for pancreatic cancer 75
Feb 22, 2016: Newly discovered HIV genome modification may put a twist on vaccine and drug design 76
Feb 10, 2016: Alcohol Also Damages the Liver by Allowing Bacteria to Infiltrate 77
Feb 08, 2016: Engineers 3D-print a New Lifelike Liver Tissue for Drug Screening 78
Jan 22, 2016: Biologists Develop Method for Antibiotic Susceptibility Testing 79
Jan 12, 2016: New NIH awards will support development of therapeutic alternatives to traditional antibiotics 81
Product News 83
Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 83
Aug 31, 2016: Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma 84
Apr 11, 2017: ‘Neuron-reading’ nanowires could accelerate development of drugs for neurological diseases 85
Other Significant Developments 86
Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
University of California San Diego, Pharmaceuticals & Healthcare, Key Facts, 2015 2
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California San Diego, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California San Diego, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California San Diego, Deals By Therapy Area, 2011 to YTD 2017 9
University of California San Diego, Medical Devices Deals, 2011 to YTD 2017 11
University of California San Diego, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
UC San Diego Health Acquires San Diego Cancer Center 15
Oxeia Biopharmaceuticals Enters Into Partnership Agreement with University of California San Diego School of Medicine 16
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 17
Biomed Realty Trust Enters into Agreement with University of California San Diego 18
Galmed Pharma Enters into Agreement with University of California 19
Janssen Pharma Enters into Agreement with University of California, San Diego 20
AccentCare Forms Joint Venture With UC San Diego Health System 21
ChemDiv Enters into R&D Agreement with UCSD, MIPT and SatRx 22
University of California and San Diego School of Medicine Partners with UC San Diego Moores Cancer Center 23
Pfizer Announces Co-Development Agreement With University Of California, San Diego 24
Regulus Therapeutics Enters Into Collaboration With University of California 26
Creative Medical Technologies Enters into Licensing Agreement with University of California, San Diego 27
Oncternal Therapeutics Enters into Licensing Agreement with University of California 28
Curtana Pharma Enters into Licensing Agreement with University of California San Diego 29
Abreos Biosciences Enter into License Agreement with University of California San 30
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 31
DesignMedix Enters into Licensing Agreement with University of California, San Diego 32
PsychoGenics Enters into Licensing Agreement with University of California, San Diego 33
Forge Therapeutics Enters into Licensing Agreement with University of California San Diego 34
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine for Transgenic Mouse Model of a-Synucleinopathies 35
PsychoGenics Enters into Licensing Agreement with University of California, San Diego School of Medicine 36
Batu Biologics Enters into Licensing Agreement with University of California, San Diego 37
PaxVax Enters into Licensing Agreement with University Of California, San Diego 38
SomPharma Enters into Licensing Agreement with University of California, San Diego 39
Solstice Biologics Enters Into Licensing Agreement With University of California, San Diego 40
Arytha Biosciences Enters into Licensing Agreement with University of California, San Diego 41
DevaCell Enters into Licensing Agreement with University of California, San Diego 42
Sanofi Pasteur Enters Into Licensing Agreement With University of California, San Diego 43
University of California San Diego, Key Competitors 44
University of California San Diego, Key Employees 45
University of California San Diego, Subsidiaries 46

★海外企業調査レポート[University of California San Diego-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Implanet SA (IMPL):医療機器:M&Aディール及び事業提携情報
    Summary Implanet SA (Implanet) is a medical device company that designs, manufactures and markets orthopaedic products. The company offers spine, knee and arthroscopy products. Its spine products are used for the treatment of spinal disorders and spinal fusion surgery. Implanet offers resorbable anc …
  • Central Rand Gold Ltd:企業の戦略・SWOT・財務情報
    Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • High Peak Royalties Limited (HPR)-エネルギー分野:企業M&A・提携分析
    Summary High Peak Royalties Limited (High Peak) is a utility company that builds a portfolio of diversified resource royalties with projects in exploration, pre-production and producing phases. It assesses a regular flow of potential royalty investments across the resources sector. The company has r …
  • Nexstar Media Group, Inc. (NXST):企業の財務・戦略的SWOT分析
    Nexstar Media Group, Inc. (NXST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Taisei Corporation:企業の戦略・SWOT・財務分析
    Taisei Corporation - Strategy, SWOT and Corporate Finance Report Summary Taisei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Optimum General Inc.
    Optimum General Inc. - Strategy, SWOT and Corporate Finance Report Summary Optimum General Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ceres Power Holdings plc (CWR):企業の財務・戦略的SWOT分析
    Summary Ceres Power Holdings Plc (Ceres Power) operates as an alternative energy company that develops low cost and next generation fuel cell technologies. The company carries out developing steel cell a fuel cell technology that converts natural gas and hydrogen fuel directly into electrical power …
  • Valora Holding AG (VALN):企業の財務・戦略的SWOT分析
    Valora Holding AG (VALN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Azimut Exploration Inc (AZM):企業の財務・戦略的SWOT分析
    Summary Azimut Exploration Inc (AEI) is a mining company that offers exploration and development of mineral resources. The company carries out the business of acquisition, exploration, and development of gold, copper, silver, chromium, uranium and rare earth element properties. It also offers projec …
  • Amicus Therapeutics Inc (FOLD):製薬・医療:M&Aディール及び事業提携情報
    Summary Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lea …
  • El Paso Electric Company (EE):企業の財務・戦略的SWOT分析
    El Paso Electric Company (EE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Jyoti Structures Ltd (JYOTISTRUC)-エネルギー分野:企業M&A・提携分析
    Summary Jyoti Structures Ltd (JSL) is a turnkey engineering, procurement, and construction (EPC) services provider that designs, tests, manufactures, sources, constructs, and supplies transmission lines, substations, and microwave towers. It designs HVDC and river crossing transmission towers, subst …
  • Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) t …
  • Philip Morris International Inc.:企業の戦略・SWOT・財務情報
    Philip Morris International Inc. - Strategy, SWOT and Corporate Finance Report Summary Philip Morris International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Navistar International Corporation:企業の戦略・SWOT・財務情報
    Navistar International Corporation - Strategy, SWOT and Corporate Finance Report Summary Navistar International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Severstal:企業の戦略・SWOT・財務分析
    Severstal - Strategy, SWOT and Corporate Finance Report Summary Severstal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Meketa Investment Group:企業の戦略・SWOT・財務分析
    Meketa Investment Group - Strategy, SWOT and Corporate Finance Report Summary Meketa Investment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sherritt International Corp (S):石油・ガス:M&Aディール及び事業提携情報
    Summary Sherritt International Corp (Sherritt) is a natural resources company. It carries out mining and refining activities for the production of nickel and cobalt from lateritic ores with ownership stake in Moa Joint Venture and Ambatovy Joint Venture. The company also explores, develops and produ …
  • Realty Income Corporation:企業のM&A・事業提携・投資動向
    Realty Income Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Realty Income Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Icagen Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Icagen Inc (Icagen) (formerly known as XRpro Sciences, Inc.) is a biopharmaceutical company which develops drug candidates to unmet medical needs. The company discovers drug for clinical stage across multiple therapeutics and ion class channel classes. The company provides technologies inclu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆